ClinicalTrials.gg
CompletedNCT02275065Updated Nov 9, 2020Results posted

Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Bictegravir (GS-9883) in Human Immunodeficiency Virus (HIV)-1 Infected Participants

A Phase 1 interventional study of Bictegravir and Placebo in HIV-1 Infection, sponsored by Gilead Sciences. Completed at 16 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-11-09.

Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The primary objective of the study is to investigate the short-term antiviral potency of bictegravir at multiple doses in antiretroviral (ART) treatment-naive adult participants and participants who are ART-experienced but integrase strand transfer inhibitor (INSTI) naive.

02

Conditions studied

  • HIV-1 Infection

Keywords

  • HIV-1 Infected
  • Adults
  • Treatment Naive
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • No current or prior anti- treatment, including ART medications received for prevention (preexposure prophylaxis [PrEP]), or postexposure prophylaxis (PEP) within 12 weeks of screening
  • Plasma HIV-1 ribonucleic acid (RNA) ≥ 10,000 copies/mL but ≤ 400,000 copies/mL at screening
  • Cluster of differentiation 4+ (CD4+) cell count > 200 cells/mm\^3

Key Exclusion Criteria:

  • Anticipated to start HIV-1 therapy during the study period
  • Active participation in another study of or approved ART agents
  • A new acquired immunodeficiency syndrome (AIDS)-defining condition diagnosed within the 30 days prior to screening
  • Participants with positive antibody at screening
  • Chronic virus (HBV) infection
  • Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 42 days prior to Day 1 (baseline)

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Bictegravir 5 mg

    Bictegravir 5 mg (1 × 5 mg tablet) for 10 days

    Drug: Bictegravir

  • Experimental
    Bictegravir 25 mg

    Bictegravir 25 mg (1 × 25 mg tablet) for 10 days

    Drug: Bictegravir

  • Experimental
    Bictegravir 50 mg

    Bictegravir 50 mg (2 × 25 mg tablets) for 10 days

    Drug: Bictegravir

  • Experimental
    Bictegravir 100 mg

    Bictegravir 100 mg (1 × 100 mg tablet) for 10 days

    Drug: Bictegravir

  • Placebo comparator
    Placebo

    Placebo matched to bictegravir tablet for 10 days

    Drug: Placebo

Interventions

  • Bictegravir tablet(s) administered orally once daily

  • DrugPlacebo

    Placebo to match bictegravir administered orally once daily

06

What researchers measure

Primary outcomes

  1. Time-Weighted Average Change From Baseline up to Day 11 (DAVG11) in Plasma HIV-1 RNA

    DAVG11 was defined as the time-weighted average between the first postbaseline value through the last available on-treatment (ie, the last dose date + 1) value up to Day 11 minus the baseline value in plasma HIV-1 RNA (log10 copies/mL). All HIV-1 RNA data up to Day 11 were used for this analysis. DAVG11 was calculated using the trapezoidal rule and the area-under-the-curve concept.

    Time frame: Baseline up to Day 11

Secondary outcomes

  1. Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (AEs)

    Time frame: First dose date up to last dose date plus 30 days (Maximum: 40 days)

  2. Percentage of Participants Who Experienced Graded Laboratory Abnormalities

    A treatment-emergent graded laboratory abnormality was defined as an increase of at least 1 toxicity grade from predose assessment and occurring after the predose visit and on or before the date of the last dose of study drug plus 30 days. If the predose assessment was missing, then any abnormality of at least Grade 1 associated with the study drug was considered a treatment-emergent graded laboratory abnormality. The most severe graded abnormality from all tests was counted for each participant.

    Time frame: First dose date up to last dose date plus 30 days (Maximum: 40 days)

  3. Maximum Reduction From Baseline Through Day 17 in Plasma HIV-1 RNA

    Maximum reduction from baseline was defined as the minimum of change from baseline in plasma HIV-1 RNA (i.e. smallest change in HIV-RNA from baseline).

    Time frame: Baseline to Day 17

  4. Viral Decay Slope in Plasma HIV-1 RNA

    Viral Decay Slope = (log10 \[HIV-1 RNA on Day x\] - log10 \[HIV-1 RNA on Day 1\]) / (x-1), where x is the collection day of the last available on treatment HIV-1 RNA collected up to Day 7.

    Time frame: Baseline up to Day 11

  5. Percentage of Participants With HIV-1 RNA < 50 Copies/mL

    Time frame: Day 17

  6. Pharmacokinetic (PK) Parameter: Cmax of Bictegravir Following Single-Dose and Multiple-Dose Administration

    Cmax is defined as the maximum concentration of drug.

    Time frame: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 1 for single dose and Day 10 for multiple dose

  7. PK Parameter: Tmax of Bictegravir Following Single-Dose and Multiple-Dose Administration

    Tmax is defined as the time (observed time point) of Cmax.

    Time frame: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 1 for single dose and Day 10 for multiple dose

  8. PK Parameter: AUC0-24 of Bictegravir Following Single-Dose Administration

    AUC0-24 is defined as the concentration of drug over time from time zero to time 24 hours.

    Time frame: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 1

  9. PK Parameter: AUClast of Bictegravir Following Single-Dose Administration

    AUClast is defined as the concentration of drug from time zero to the last observable concentration.

    Time frame: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 1

  10. PK Parameter: AUCtau of Bictegravir Following Multiple-Dose Administration

    AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).

    Time frame: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 10

  11. PK Parameter: t1/2 of Bictegravir Following Multiple-Dose Administration

    t1/2 is defined as the estimate of the terminal elimination half-life of the drug.

    Time frame: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 10

  12. PK Parameter: Ctau of Bictegravir Following Multiple-Dose Administration

    Ctau is defined as the observed drug concentration at the end of the dosing interval.

    Time frame: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 10

  13. PK Parameter: CLss/F of Bictegravir Following Multiple-Dose Administration

    CLss/F is defined as the apparent oral clearance following multiple-dose administration of the drug.

    Time frame: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 10

  14. PK Parameter: AR_AUC of Bictegravir Following Multiple-Dose Administration

    Accumulation ratio of AUC (AR_AUC) = AUCtau on Day 10 / AUC0-24 on Day 1. Percentage of accumulation ratio has been reported.

    Time frame: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 1 and 10

  15. PK Parameter: AR_Cmax of Bictegravir Following Multiple-Dose Administration

    Accumulation ratio of Cmax (AR_Cmax) = Cmax on Day 10 / Cmax on Day 1. Percentage of accumulation ratio has been reported.

    Time frame: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 1 and 10

  16. PK/Pharmacodynamic (PD) Analysis: Pearson Correlation Between AUCtau of Bictegravir and DAVG11 in Plasma HIV-1 RNA

    AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval). DAVG11 was defined as the time-weighted average between the first postbaseline value through the last available on-treatment (ie, the last dose date + 1) value up to Day 11 minus the baseline value in plasma HIV-1 RNA (log10 copies/mL).

    Time frame: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 10

07

Results

Posted Oct 8, 2020

Participant flow

Participants were enrolled at study sites in United States. The first participant was screened on 24 October 2014. The last study visit occurred on 29 January 2015.

Participant flow — Overall Study
MilestoneBictegravir 5 mgBictegravir 25 mgBictegravir 50 mgBictegravir 100 mgPlacebo
Started54554
Completed44444
Not completed10110
Withdrew: Randomized but not treated10110

Outcome measures

PrimaryTime-Weighted Average Change From Baseline up to Day 11 (DAVG11) in Plasma HIV-1 RNA

DAVG11 was defined as the time-weighted average between the first postbaseline value through the last available on-treatment (ie, the last dose date + 1) value up to Day 11 minus the baseline value in plasma HIV-1 RNA (log10 copies/mL). All HIV-1 RNA data up to Day 11 were used for this analysis. DAVG11 was calculated using the trapezoidal rule and the area-under-the-curve concept.

Time frame:
Baseline up to Day 11
Reported as:
Mean · log10 copies/mL
Time-Weighted Average Change From Baseline up to Day 11 (DAVG11) in Plasma HIV-1 RNA
log10 copies/mLBictegravir 5 mgBictegravir 25 mgBictegravir 50 mgBictegravir 100 mgPlacebo
Baseline4.26 ± 0.1574.64 ± 0.4984.42 ± 0.4584.71 ± 1.0404.50 ± 0.407
Change at Day 11-0.92 ± 0.104-1.33 ± 0.174-1.37 ± 0.310-1.61 ± 0.256-0.01 ± 0.144
Statistical analysis
  • Bictegravir 5 mg vs Placebo · t-test, 2 sided · p = <0.001 (Comparison was made using the t-test at a 2-sided 0.05 significance level.)
  • Bictegravir 25 mg vs Placebo · t-test, 2 sided · p = <0.001 (Comparison was made using the t-test at a 2-sided 0.05 significance level.)
  • Bictegravir 50 mg vs Placebo · t-test, 2 sided · p = <0.001 (Comparison was made using the t-test at a 2-sided 0.05 significance level.)
  • Bictegravir 100 mg vs Placebo · t-test, 2 sided · p = <0.001 (Comparison was made using the t-test at a 2-sided 0.05 significance level.)
SecondaryPercentage of Participants Who Experienced Treatment-Emergent Adverse Events (AEs)
Time frame:
First dose date up to last dose date plus 30 days (Maximum: 40 days)
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (AEs)
percentage of participantsBictegravir 5 mgBictegravir 25 mgBictegravir 50 mgBictegravir 100 mgPlacebo
Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (AEs)75.025.050.050.025.0
SecondaryPercentage of Participants Who Experienced Graded Laboratory Abnormalities

A treatment-emergent graded laboratory abnormality was defined as an increase of at least 1 toxicity grade from predose assessment and occurring after the predose visit and on or before the date of the last dose of study drug plus 30 days. If the predose assessment was missing, then any abnormality of at least Grade 1 associated with the study drug was considered a treatment-emergent graded laboratory abnormality. The most severe graded abnormality from all tests was counted for each participant.

Time frame:
First dose date up to last dose date plus 30 days (Maximum: 40 days)
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Graded Laboratory Abnormalities
percentage of participantsBictegravir 5 mgBictegravir 25 mgBictegravir 50 mgBictegravir 100 mgPlacebo
Percentage of Participants Who Experienced Graded Laboratory Abnormalities75.025.0025.050.0
SecondaryMaximum Reduction From Baseline Through Day 17 in Plasma HIV-1 RNA

Maximum reduction from baseline was defined as the minimum of change from baseline in plasma HIV-1 RNA (i.e. smallest change in HIV-RNA from baseline).

Time frame:
Baseline to Day 17
Reported as:
Mean · log10 copies/mL
Maximum Reduction From Baseline Through Day 17 in Plasma HIV-1 RNA
log10 copies/mLBictegravir 5 mgBictegravir 25 mgBictegravir 50 mgBictegravir 100 mgPlacebo
Maximum Reduction From Baseline Through Day 17 in Plasma HIV-1 RNA-1.52 ± 0.079-2.18 ± 0.241-2.31 ± 0.191-2.91 ± 0.526-0.12 ± 0.177
Statistical analysis
  • Bictegravir 5 mg vs Placebo · t-test, 2 sided · p = <0.001 (Comparison was made using the t-test at a 2-sided 0.05 significance level.)
  • Bictegravir 25 mg vs Placebo · t-test, 2 sided · p = <0.001 (Comparison was made using the t-test at a 2-sided 0.05 significance level.)
  • Bictegravir 50 mg vs Placebo · t-test, 2 sided · p = <0.001 (Comparison was made using the t-test at a 2-sided 0.05 significance level.)
  • Bictegravir 100 mg vs Placebo · t-test, 2 sided · p = <0.001 (Comparison was made using the t-test at a 2-sided 0.05 significance level.)
SecondaryViral Decay Slope in Plasma HIV-1 RNA

Viral Decay Slope = (log10 \[HIV-1 RNA on Day x\] - log10 \[HIV-1 RNA on Day 1\]) / (x-1), where x is the collection day of the last available on treatment HIV-1 RNA collected up to Day 7.

Time frame:
Baseline up to Day 11
Reported as:
Mean · log10 copies/mL
Viral Decay Slope in Plasma HIV-1 RNA
log10 copies/mLBictegravir 5 mgBictegravir 25 mgBictegravir 50 mgBictegravir 100 mgPlacebo
Viral Decay Slope in Plasma HIV-1 RNA-0.184 ± 0.0134-0.252 ± 0.0277-0.272 ± 0.0580-0.315 ± 0.0413-0.011 ± 0.0200
Statistical analysis
  • Bictegravir 5 mg vs Placebo · t-test, 2 sided · p = <0.001 (Comparison was made using the t-test at a 2-sided 0.05 significance level.)
  • Bictegravir 25 mg vs Placebo · t-test, 2 sided · p = <0.001 (Comparison was made using the t-test at a 2-sided 0.05 significance level.)
  • Bictegravir 50 mg vs Placebo · t-test, 2 sided · p = <0.001 (Comparison was made using the t-test at a 2-sided 0.05 significance level.)
  • Bictegravir 100 mg vs Placebo · t-test, 2 sided · p = <0.001 (Comparison was made using the t-test at a 2-sided 0.05 significance level.)
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL
Time frame:
Day 17
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL
percentage of participantsBictegravir 5 mgBictegravir 25 mgBictegravir 50 mgBictegravir 100 mgPlacebo
Percentage of Participants With HIV-1 RNA < 50 Copies/mL0025.050.00
SecondaryPharmacokinetic (PK) Parameter: Cmax of Bictegravir Following Single-Dose and Multiple-Dose Administration

Cmax is defined as the maximum concentration of drug.

Time frame:
0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 1 for single dose and Day 10 for multiple dose
Reported as:
Mean · ng/mL
Pharmacokinetic (PK) Parameter: Cmax of Bictegravir Following Single-Dose and Multiple-Dose Administration
ng/mLBictegravir 5 mgBictegravir 25 mgBictegravir 50 mgBictegravir 100 mg
Single-Dose493.3 ± 72.122565.0 ± 331.314957.5 ± 667.607367.5 ± 2293.90
Multiple-Dose741.5 ± 134.653475.0 ± 712.676080.0 ± 1323.2012235.0 ± 3040.98
SecondaryPK Parameter: Tmax of Bictegravir Following Single-Dose and Multiple-Dose Administration

Tmax is defined as the time (observed time point) of Cmax.

Time frame:
0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 1 for single dose and Day 10 for multiple dose
Reported as:
Median · hours
PK Parameter: Tmax of Bictegravir Following Single-Dose and Multiple-Dose Administration
hoursBictegravir 5 mgBictegravir 25 mgBictegravir 50 mgBictegravir 100 mg
Single-Dose1.00 (1.00 to 1.25)1.83 (1.33 to 2.50)1.75 (1.50 to 2.50)1.50 (1.25 to 1.75)
Multiple-Dose1.50 (0.75 to 3.00)1.25 (1.00 to 1.50)1.75 (1.25 to 2.50)2.74 (1.25 to 3.99)
SecondaryPK Parameter: AUC0-24 of Bictegravir Following Single-Dose Administration

AUC0-24 is defined as the concentration of drug over time from time zero to time 24 hours.

Time frame:
0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 1
Reported as:
Mean · ng*hr/mL
PK Parameter: AUC0-24 of Bictegravir Following Single-Dose Administration
ng*hr/mLBictegravir 5 mgBictegravir 25 mgBictegravir 50 mgBictegravir 100 mg
PK Parameter: AUC0-24 of Bictegravir Following Single-Dose Administration6262.2 ± 1432.1731291.8 ± 3113.9168476.5 ± 11667.4194588.5 ± 27376.40
SecondaryPK Parameter: AUClast of Bictegravir Following Single-Dose Administration

AUClast is defined as the concentration of drug from time zero to the last observable concentration.

Time frame:
0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 1
Reported as:
Mean · ng*hr/mL
PK Parameter: AUClast of Bictegravir Following Single-Dose Administration
ng*hr/mLBictegravir 5 mgBictegravir 25 mgBictegravir 50 mgBictegravir 100 mg
PK Parameter: AUClast of Bictegravir Following Single-Dose Administration6295.5 ± 1496.5931401.0 ± 3123.5968485.6 ± 11649.3794827.0 ± 27262.26
SecondaryPK Parameter: AUCtau of Bictegravir Following Multiple-Dose Administration

AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).

Time frame:
0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 10
Reported as:
Mean · ng*hr/mL
PK Parameter: AUCtau of Bictegravir Following Multiple-Dose Administration
ng*hr/mLBictegravir 5 mgBictegravir 25 mgBictegravir 50 mgBictegravir 100 mg
PK Parameter: AUCtau of Bictegravir Following Multiple-Dose Administration9983.0 ± 2664.7748950.3 ± 19592.4187538.4 ± 28649.77178901.7 ± 31865.15
SecondaryPK Parameter: t1/2 of Bictegravir Following Multiple-Dose Administration

t1/2 is defined as the estimate of the terminal elimination half-life of the drug.

Time frame:
0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 10
Reported as:
Median · hours
PK Parameter: t1/2 of Bictegravir Following Multiple-Dose Administration
hoursBictegravir 5 mgBictegravir 25 mgBictegravir 50 mgBictegravir 100 mg
PK Parameter: t1/2 of Bictegravir Following Multiple-Dose Administration20.79 (17.15 to 23.80)15.86 (14.07 to 19.37)17.84 (15.50 to 20.51)20.88 (17.91 to 24.47)
SecondaryPK Parameter: Ctau of Bictegravir Following Multiple-Dose Administration

Ctau is defined as the observed drug concentration at the end of the dosing interval.

Time frame:
0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 10
Reported as:
Mean · ng/mL
PK Parameter: Ctau of Bictegravir Following Multiple-Dose Administration
ng/mLBictegravir 5 mgBictegravir 25 mgBictegravir 50 mgBictegravir 100 mg
PK Parameter: Ctau of Bictegravir Following Multiple-Dose Administration225.3 ± 84.571052.3 ± 568.902053.0 ± 977.354520.0 ± 991.90
SecondaryPK Parameter: CLss/F of Bictegravir Following Multiple-Dose Administration

CLss/F is defined as the apparent oral clearance following multiple-dose administration of the drug.

Time frame:
0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 10
Reported as:
Mean · mL/hr
PK Parameter: CLss/F of Bictegravir Following Multiple-Dose Administration
mL/hrBictegravir 5 mgBictegravir 25 mgBictegravir 50 mgBictegravir 100 mg
PK Parameter: CLss/F of Bictegravir Following Multiple-Dose Administration523.8 ± 115.43567.3 ± 196.72621.9 ± 211.73570.6 ± 87.57
SecondaryPK Parameter: AR_AUC of Bictegravir Following Multiple-Dose Administration

Accumulation ratio of AUC (AR_AUC) = AUCtau on Day 10 / AUC0-24 on Day 1. Percentage of accumulation ratio has been reported.

Time frame:
0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 1 and 10
Reported as:
Mean · percentage of AR_AUC
PK Parameter: AR_AUC of Bictegravir Following Multiple-Dose Administration
percentage of AR_AUCBictegravir 5 mgBictegravir 25 mgBictegravir 50 mgBictegravir 100 mg
PK Parameter: AR_AUC of Bictegravir Following Multiple-Dose Administration160.2 ± 25.86157.4 ± 59.76125.3 ± 20.92193.3 ± 22.44
SecondaryPK Parameter: AR_Cmax of Bictegravir Following Multiple-Dose Administration

Accumulation ratio of Cmax (AR_Cmax) = Cmax on Day 10 / Cmax on Day 1. Percentage of accumulation ratio has been reported.

Time frame:
0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 1 and 10
Reported as:
Mean · percentage of AR_Cmax
PK Parameter: AR_Cmax of Bictegravir Following Multiple-Dose Administration
percentage of AR_CmaxBictegravir 5 mgBictegravir 25 mgBictegravir 50 mgBictegravir 100 mg
PK Parameter: AR_Cmax of Bictegravir Following Multiple-Dose Administration149.8 ± 6.61138.5 ± 37.40122.0 ± 13.31168.4 ± 16.15
SecondaryPK/Pharmacodynamic (PD) Analysis: Pearson Correlation Between AUCtau of Bictegravir and DAVG11 in Plasma HIV-1 RNA

AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval). DAVG11 was defined as the time-weighted average between the first postbaseline value through the last available on-treatment (ie, the last dose date + 1) value up to Day 11 minus the baseline value in plasma HIV-1 RNA (log10 copies/mL).

Time frame:
0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 10
Reported as:
Number · correlation coefficient
PK/Pharmacodynamic (PD) Analysis: Pearson Correlation Between AUCtau of Bictegravir and DAVG11 in Plasma HIV-1 RNA
correlation coefficientBictegravir 5 mgBictegravir 25 mgBictegravir 50 mgBictegravir 100 mg
PK/Pharmacodynamic (PD) Analysis: Pearson Correlation Between AUCtau of Bictegravir and DAVG11 in Plasma HIV-1 RNA-1.0000.275-0.9400.713

Adverse events

Collected over First dose date up to last dose date plus 30 days (Maximum: 40 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bictegravir 5 mg0/4 (0%)0/4 (0%)3/4 (75%)
Bictegravir 25 mg0/4 (0%)0/4 (0%)1/4 (25%)
Bictegravir 50 mg0/4 (0%)0/4 (0%)2/4 (50%)
Bictegravir 100 mg0/4 (0%)0/4 (0%)2/4 (50%)
Placebo0/4 (0%)0/4 (0%)1/4 (25%)
Most frequent other events
Most frequent other events
EventBictegravir 5 mgBictegravir 25 mgBictegravir 50 mgBictegravir 100 mgPlacebo
DiarrhoeaGastrointestinal disorders1/40/40/41/40/4
FatigueGeneral disorders0/40/41/40/40/4
NasopharyngitisInfections and infestations0/40/40/40/41/4
Upper respiratory tract infectionInfections and infestations1/40/40/40/40/4
Arthropod biteInjury, poisoning and procedural complications0/40/40/41/40/4
Blood creatine phosphokinase increasedInvestigations1/40/40/40/40/4
Musculoskeletal painMusculoskeletal and connective tissue disorders1/40/40/40/40/4
HeadacheNervous system disorders1/41/40/41/41/4
PapuleSkin and subcutaneous tissue disorders0/40/41/40/40/4

Baseline characteristics

The Safety Analysis Set included participants who were randomized and received at least 1 dose of bictegravir or matched placebo.

Age, Continuous
Age, Continuous(years)Bictegravir 5 mgBictegravir 25 mgBictegravir 50 mgBictegravir 100 mgPlaceboTotal
Mean29 ± 4.044 ± 16.534 ± 11.536 ± 11.224 ± 3.233 ± 11.6
Sex: Female, Male
Sex: Female, Male(Participants)Bictegravir 5 mgBictegravir 25 mgBictegravir 50 mgBictegravir 100 mgPlaceboTotal
Female001001
Male4434419
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Bictegravir 5 mgBictegravir 25 mgBictegravir 50 mgBictegravir 100 mgPlaceboTotal
Hispanic or Latino221016
Not Hispanic or Latino2234314
Unknown or Not Reported000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Bictegravir 5 mgBictegravir 25 mgBictegravir 50 mgBictegravir 100 mgPlaceboTotal
Race — Black011136
Race — White4233113
Race — Other010001
Human Immunodeficiency Virus, Type 1 Ribonucleic Acid (HIV-1 RNA)
Human Immunodeficiency Virus, Type 1 Ribonucleic Acid (HIV-1 RNA)(log10 copies/mL)Bictegravir 5 mgBictegravir 25 mgBictegravir 50 mgBictegravir 100 mgPlaceboTotal
Mean3.76 ± 1.0204.64 ± 0.4984.42 ± 0.4584.71 ± 1.0404.50 ± 0.4074.40 ± 0.745
08

Study locations

16 sites
  • Berkeley, California, United States
  • Davis, California, United States
  • Long Beach, California, United States
  • Los Angeles, California, United States
  • San Francisco, California, United States
  • Washington, District of Columbia, United States
  • Fort Lauderdale, Florida, United States
  • Orlando, Florida, United States
  • Vero Beach, Florida, United States
  • West Palm Beach, Florida, United States
  • Atlanta, Georgia, United States
  • Berkley, Michigan, United States
  • Newark, New Jersey, United States
  • Santa Fe, New Mexico, United States
  • Dallas, Texas, United States
  • Seattle, Washington, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2014 to primary completion in Jan 2015, 2 months.

Results were first posted in Oct 2020, 5 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2014
First posted
Oct 27, 2014
StartActual
Oct 24, 2014
Primary completionActual
Jan 23, 2015
CompletionActual
Jan 29, 2015
Results first posted
Oct 8, 2020
Last update
Nov 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02275065
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Oct 27, 2014
Start date
Oct 24, 2014
Primary completion
Jan 23, 2015
Completion
Jan 29, 2015
Results posted
Oct 8, 2020
Last update
Nov 9, 2020

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bictegravir

Start the discussion